STOCK TITAN
  1. Home
  2. News
  3. ALLO

Allogene Therapeutics Inc - ALLO STOCK NEWS

Welcome to our dedicated news page for Allogene Therapeutics (Ticker: ALLO), a resource for investors and traders seeking the latest updates and insights on Allogene Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Allogene Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Allogene Therapeutics's position in the market.

News
Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology
Rhea-AI Summary
Allogene Therapeutics, Inc. (Nasdaq: ALLO) has announced positive results from the Phase 1 ALPHA/ALPHA2 trials for ALLO-647, demonstrating its potential to yield durable responses and a safety profile comparable to approved autologous CAR T therapies. The company also received Fast Track Designation for ALLO-647 for use in adult patients with relapsed/refractory Large B-Cell Lymphoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Allogene Therapeutics Announces Participation in December Investor Conference
Rhea-AI Summary
Allogene Therapeutics, Inc. (Nasdaq: ALLO) will participate in the JMP Securities Hematology and Oncology Summit on December 6, 2023, to showcase its allogeneic CAR T (AlloCAR T™) products for cancer. The webcast will be available on the company's website for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.23%
Tags
none
-
News
Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual Meeting
Rhea-AI Summary
Allogene Therapeutics presented preclinical data on their AlloCAR T product candidate targeting Claudin18.2-positive gastric and pancreatic tumors. The data showed potent activity in vitro and in vivo, suggesting the potential for clinical benefit with a single off-the-shelf infusion. ALLO-182, the lead candidate, is currently in the IND-enabling phase of development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.85%
Tags
clinical trial
News
Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak™ and Dagger™ Technologies at the Society for Immunotherapy of Cancer Annual Meeting
Rhea-AI Summary
Allogene Therapeutics presented data on their Cloak and Dagger technologies at the SITC Annual Meeting. These technologies aim to enhance the performance of AlloCAR T cell candidates by reducing rejection by the immune system. The Cloak technology prevents recognition by host T cells, while the Dagger technology enables dual specificity against CD70-positive host immune cells and CD19-positive tumor cells. These advancements have the potential to make CAR T therapies more scalable and accessible to patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.85%
Tags
clinical trial
-
News
Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update
Rhea-AI Summary
Allogene Therapeutics, Inc. provided a corporate update and reported financial results for Q3 2023. They ended the quarter with $497.7 million in cash, cash equivalents, and investments. The company expects a decrease in cash of approximately $230 million in 2023, with a cash runway projected into the second half of 2025. They announced preclinical posters to be presented at upcoming conferences, highlighting the potential of their AlloCAR T platform and providing updates on their clinical trials for ALLO-501A and ALLO-647. The company also announced appointments to its leadership team.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.85%
Tags
earnings
-
News
Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of Hematology
Rhea-AI Summary
Allogene Therapeutics, Inc. will present two poster presentations at the 65th Annual Meeting of the American Society of Hematology (ASH). The first poster is a safety review of all 85 patients treated in the Phase 1 ALPHA/ALPHA2 studies in relapsed/refractory Large B Cell Lymphoma (LBCL) and follicular lymphoma (FL). The second poster showcases translational results from ALPHA2, comparing expansion kinetics among 11 allogeneic CAR T recipients. These presentations highlight the importance of lymphodepletion in allogeneic cell therapy and provide insights into improving CAR T expansion and efficacy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.95%
Tags
none
News
Allogene Therapeutics Announces Participation in November Investor Conferences
Rhea-AI Summary
Allogene Therapeutics, Inc. will participate in two investor conferences in November. The first conference is TD Cowen's 7th Annual Fall Oncology Innovation Summit on November 3rd, and the second is Jefferies London Healthcare Conference on November 15th. Webcasts of the conferences will be available on the company's website, and replays will be accessible for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.09%
Tags
none
-
News
Allogene Therapeutics to Report Third Quarter 2023 Financial Results on November 2, 2023
Rhea-AI Summary
Allogene Therapeutics will report third quarter 2023 financial results on November 2, 2023, followed by a conference call and webcast at 2:00 PM PT/5:00 PM ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
conferences earnings
-
News
Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T™ Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Rhea-AI Summary
Allogene Therapeutics announces three preclinical poster presentations at the Society for Immunotherapy of Cancer Annual Meeting. The presentations will focus on next-generation AlloCAR T platform technologies and the ALLO-182 solid tumor product candidate. The work aims to enhance engraftment and expansion of AlloCAR T products, potentially improving their persistence and anti-tumor activity. This could expand the potential of off-the-shelf CAR T products and reduce the intensity of conditioning therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.93%
Tags
none
News
Allogene Therapeutics Announces Participation in September Investor Conference
Rhea-AI Summary
Allogene Therapeutics to participate in Baird 2023 Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
none
Stock ALLO logo
Allogene Therapeutics Inc

Nasdaq:ALLO

ALLO Rankings

#2986 Ranked by Market Cap
#5239 Ranked by Stock Gains
N/A Ranked by Dividends

ALLO Stock Data

591.82M
111.00M
22.44%
73.63%
18.11%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
South San Francisco

About ALLO

allogene therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor t-cell (car t) therapy directed at blood cancers and solid tumors. founded and led by former kite pharma executives who bring unrivaled clinical development acumen in cell therapy, allogene is well-positioned to further the potential of allogeneic cell therapy for patients. allogeneic car t therapies are engineered from cells of healthy donors and stored for “off-the-shelf” use in patients. this approach eliminates the need to create personalized therapy from a patient’s own cells, simplifies manufacturing, and reduces the time patients must wait for car t treatment. the allogene portfolio includes 16 pre-clinical t cell therapy assets and ucart19, an allogeneic car t therapy currently in phase 1 development for the treatment of acute lymphoblastic leukemia (all). through its notable partnerships, allogene le